stonks4u
Log inSign up free
PRAX logo

PRAX Praxis Precision Medicines, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$389.99
+23.18 (+6.32%)

Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABA…

Market Cap: $10.87Bwww.praxismedicines.com

Price

No data yet.

Signal Score (90d)

100
100
Aug 17Aug 17

Revenue

$0.00
$0.00$2.49M$4.98M$7.46M
Sep 2021Jun 2026

Quote

Day Range
$370.08 – $391.64
52-Week Range
$37.19 – $392.09
Volume
$245.7K
Market Cap
$10.87B
50-Day Avg
$311.71
200-Day Avg
$294.30
Prev Close
$366.81
Open
$371.97

Valuation & Ratios

P/E Ratio
-21.86
EPS
$-13.48
P/B Ratio
7.55
P/S Ratio
0.00
Debt/Equity
0.00
Current Ratio
10.22
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-34.5%
Return on Assets
-32.3%
FCF Yield
-3.8%
EV/EBITDA
-20.70

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-303.27M$-13.48
2024$8.55M$-182.82M$-10.21
2023$2.45M$-123.28M$-18.69
2022$0.00$-214.03M$-69.33
2021$0.00$-167.06M$-58.96

Social Signal Score

50
5d
51
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
rss: 1

Earnings

Wed, Nov 4(in 3 months)

Consensus estimate $-3.65 per share

4of 7 quarters beat consensus

Typical surprise +2.6% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 6$-2.87 vs $-3.67beat
  • Thu, May 7$-3.20 vs $-3.58beat
  • Thu, Feb 19$-3.50 vs $-3.13miss
  • Wed, Nov 5$-3.36 vs $-3.45beat
  • Mon, Aug 4$-3.31 vs $-3.40beat
  • Fri, May 2$-3.29 vs $-3.20miss

Estimates and results for PRAX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by PRAX officers and directors.

Bought
—

0 trades

Sold
$10.7m

17 trades

  • Desimone Jillsold
    director·10 @ $301.44·$3k·Jun 24, 2026·filing
  • Desimone Jillsold
    director·120 @ $303.13·$36k·Jun 24, 2026·filing
  • Desimone Jillsold
    director·320 @ $305.31·$98k·Jun 24, 2026·filing
  • Desimone Jillsold
    director·683 @ $306.77·$210k·Jun 24, 2026·filing
  • Desimone Jillsold
    director·1,240 @ $308.24·$382k·Jun 24, 2026·filing
  • Desimone Jillsold
    director·999 @ $309.38·$309k·Jun 24, 2026·filing
  • Desimone Jillsold
    director·1,750 @ $310.89·$544k·Jun 24, 2026·filing
  • Desimone Jillsold
    director·2,854 @ $311.91·$890k·Jun 24, 2026·filing

83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

PRAXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • News (RSS)investing·1h ago·Neutral

    Praxis Precision Medicines stock hits 52-week high at 388.27 USD

    View source ↗